1 2-Naphthoquinone Aconitic Acid Arsenic Citric Ac

證據等級: L5

預測適應症: 0 個

Multi-Component Metabolic Mixture: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This candidate is a complex 20-ingredient mixture — including Krebs cycle intermediates, trace minerals, plant extracts (ginkgo), and porcine organ extracts (lung, colon, pancreas) — with no registered indication or regulatory approval in Taiwan or the US. The TxGNN model returned no predicted indications, likely because this multi-component formulation could not be mapped to a single DrugBank entity. Without predictions, regulatory records, or safety data, a full repurposing evaluation cannot proceed at this time.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	No TxGNN prediction generated
TxGNN Prediction Score	N/A
Evidence Level	L5 (no studies; no predictions)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This entry is not a single drug but a 20-component formulation containing:

Krebs cycle organic acids: citric acid, malic acid, fumaric acid, succinic acid, pyruvic acid, aconitic acid, oxogluric acid (α-ketoglutaric acid)
Trace elements and minerals: arsenic, copper, manganese, phosphorus, tin, germanium sesquioxide, oyster shell calcium carbonate
Porcine organ extracts: Sus scrofa colon, lung, and pancreas
Plant extract: Ginkgo
Synthetic/semi-synthetic compounds: 1,2-naphthoquinone, sodium diethyl oxalacetate

The TxGNN model is designed to evaluate single drug entities mapped via DrugBank IDs. Because this formulation has no DrugBank ID and its constituent ingredients lack a unified pharmacological profile, the model could not produce a repurposing prediction. Additionally, no original indication or approved use was found in either the Taiwan or US regulatory database.

This pattern is typical of compounded preparations or traditional medicine products that exist outside standard regulatory pathways, making automated repurposing analysis structurally infeasible without first decomposing the formulation into its individual components.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Note: Several ingredients in this formulation warrant independent safety review before any clinical use:

Arsenic: narrow therapeutic index; recognized carcinogen at chronic low doses

Germanium sesquioxide: associated with nephrotoxicity in case reports

Tin: systemic toxicity risk at elevated exposure

1,2-Naphthoquinone: reactive oxidant with potential cytotoxicity

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN predictions were generated, no regulatory approvals exist, and no safety profile has been established for this formulation as a whole. The complexity of the 20-component mixture prevents standard drug repurposing evaluation.

To proceed, the following is needed:

Formulation decomposition: Evaluate each of the 20 ingredients individually through the TxGNN pipeline to identify which components may carry repurposing potential
Identity clarification: Determine whether this mixture corresponds to a named traditional medicine product (e.g., a glandular/organotherapy preparation) and locate its regulatory history
Safety audit: Conduct independent toxicology review for arsenic, germanium sesquioxide, tin, and 1,2-naphthoquinone components before any human exposure study is considered
MOA documentation: Map individual ingredient mechanisms to assess whether any coherent combined pharmacological activity can be proposed
DrugBank linkage: Attempt to link each active ingredient to a DrugBank entry to enable component-level TxGNN scoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.